These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 37057287)
21. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions. Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643 [TBL] [Abstract][Full Text] [Related]
22. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases. Lo Bello G; Pini GM; Giagnacovo M; Patriarca C Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637 [TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi. Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835 [TBL] [Abstract][Full Text] [Related]
24. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825 [TBL] [Abstract][Full Text] [Related]
25. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. Gassenmaier M; Hahn M; Metzler G; Bauer J; Yazdi AS; Keim U; Garbe C; Wagner NB; Forchhammer S Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359765 [TBL] [Abstract][Full Text] [Related]
26. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors. Lezcano C; Jungbluth AA; Busam KJ Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605 [TBL] [Abstract][Full Text] [Related]
27. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis. Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613 [TBL] [Abstract][Full Text] [Related]
28. Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas. Koch EAT; Erdmann M; Berking C; Kiesewetter F; Kramer R; Schliep S; Heppt MV Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047361 [TBL] [Abstract][Full Text] [Related]
30. Black and Brown Oro-facial Mucocutaneous Neoplasms. Natarajan E Head Neck Pathol; 2019 Mar; 13(1):56-70. PubMed ID: 30693458 [TBL] [Abstract][Full Text] [Related]
31. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi. Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527 [TBL] [Abstract][Full Text] [Related]
32. The Challenge of Melanocytic Lesions in Pediatric Patients: Clinical-Pathological Findings and the Diagnostic Value of PRAME. Umano GR; Errico ME; D'Onofrio V; Delehaye G; Trotta L; Spinelli C; Strambi S; Franco R; D'Abbronzo G; Ronchi A; Papparella A Front Oncol; 2021; 11():688410. PubMed ID: 34195089 [TBL] [Abstract][Full Text] [Related]
33. PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma. Glutsch V; Wobser M; Schilling B; Gesierich A; Goebeler M; Kneitz H Dermatopathology (Basel); 2022 May; 9(2):148-157. PubMed ID: 35645230 [TBL] [Abstract][Full Text] [Related]
34. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046 [TBL] [Abstract][Full Text] [Related]
35. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. Alomari AK; Tharp AW; Umphress B; Kowal RP J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310 [TBL] [Abstract][Full Text] [Related]
37. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions. Olds H; Utz S; Abrams J; Terrano D; Mehregan D J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798 [TBL] [Abstract][Full Text] [Related]
38. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis. LeBlanc RE; Miller DM; Zegans ME J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198 [TBL] [Abstract][Full Text] [Related]
39. Aberrant expression of HMB45 and negative PRAME expression in halo nevi. Ruby KN; Li Z; Yan S J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871 [TBL] [Abstract][Full Text] [Related]
40. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]